Insights
Search Results
Client Highlights
12.09.22
Firm Advises Arcellx on $4 Billion Collaboration with Kite
On December 9, 2022, clinical-stage biotechnology company Arcellx and Gilead-owned biopharmaceutical company Kite announced a global strategic collaboration to develop and commercialize Arcellx’s lead late-stage myeloma candidate. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
8.24.21
Wilson Sonsini Advises Tenaya Therapeutics on $207 Million IPO
On August 3, 2021, Tenaya Therapeutics, a biotechnology company with a mission to discover, develop, and deliver curative therapies that address the underlying causes of heart disease, announced the closing of its underwritten, upsized initial public offering of 13,800,000 shares of its common stock, which includes the exercise in full of the underwriters’ option to purchase 1,800,000 additional shares of its common stock, at an initial public offering price of $15.00 per share. The aggregate gross proceeds from the offering were $207.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Tenaya. All shares in the offering were offered by Tenaya. The shares began trading on the Nasdaq Global Select Market on July 30, 2021, under the ticker symbol “TNYA.”
Client Highlights
7.26.21
Firm Represents Alector in $700 Million Collaboration Agreement with GSK
On July 2, 2021, GlaxoSmithKline (GSK) and Alector announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments. Wilson Sonsini Goodrich& Rosati represented Alector in the transaction.
Client Highlights
9.12.19
Wilson Sonsini Advises Mesoblast in Strategic Partnership with Grünenthal
On September 9, 2019, Grünenthal, a global leader in pain management, and Mesoblast Limited, a world leader in allogeneic cellular medicines for inflammatory diseases, announced that they have entered into a strategic partnership to develop and commercialize MPC-06-ID, a Phase III allogeneic cell therapy candidate for the treatment of chronic low back pain due to degenerative disc disease in patients who have exhausted conservative treatment options.
Client Highlights
5.21.19
Peloton Therapeutics to Be Acquired by Merck
On May 21, 2019, Merck, a leading global biopharmaceutical company, and Peloton Therapeutics, a clinical-stage biopharmaceutical company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton in a deal potentially worth up to $2.2 billion.
Press Releases
12.04.17
Wilson Sonsini Goodrich & Rosati Elects 15 New Partners
PALO ALTO, CA (December 4, 2017)—Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, today announced that it has elected 15 new partners. The promotions will become effective on February 1, 2018.